Log In
BCIQ
Print this Print this
 

PG120

  Manage Alerts
Collapse Summary General Information
Company PanGenetics B.V.
DescriptionAntibody that agonizes the CD40 receptor
Molecular Target CD40
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationB cell lymphoma
Indication DetailsTreat B cell lymphoma and other B cell mediated diseases
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today